{"name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","slug":"academisch-medisch-centrum-universiteit-van-amsterdam-amc-uva","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Endotoxin","genericName":"Endotoxin","slug":"endotoxin","indication":"Other","status":"marketed"},{"name":"Cephalozin","genericName":"Cephalozin","slug":"cephalozin","indication":"Other","status":"marketed"},{"name":"Nanocort","genericName":"Nanocort","slug":"nanocort","indication":"Other","status":"phase_1"},{"name":"Placebo (for flucloxacillin)","genericName":"Placebo (for flucloxacillin)","slug":"placebo-for-flucloxacillin","indication":"Control comparator in clinical research (not a therapeutic indication)","status":"marketed"},{"name":"Reduced noradrenaline use","genericName":"Reduced noradrenaline use","slug":"reduced-noradrenaline-use","indication":"Septic shock or other conditions requiring vasopressor support in intensive care","status":"marketed"},{"name":"S-1 and Oxaliplatin","genericName":"S-1 and Oxaliplatin","slug":"s-1-and-oxaliplatin","indication":"Other","status":"phase_2"},{"name":"Vancomycin, Metronidazole, Ciprofloxacin","genericName":"Vancomycin, Metronidazole, Ciprofloxacin","slug":"vancomycin-metronidazole-ciprofloxacin","indication":"Other","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"immunology","drugs":[{"name":"Fixed low dose tinzaparin","genericName":"Fixed low dose tinzaparin","slug":"fixed-low-dose-tinzaparin","indication":"Thromboprophylaxis in medical patients","status":"marketed"},{"name":"Intermediate dose dalteparin","genericName":"Intermediate dose dalteparin","slug":"intermediate-dose-dalteparin","indication":"Thromboembolism prophylaxis and treatment","status":"marketed"},{"name":"Intermediate dose enoxaparin","genericName":"Intermediate dose enoxaparin","slug":"intermediate-dose-enoxaparin","indication":"Thromboprophylaxis in medical and surgical patients","status":"marketed"},{"name":"Low dose dalteparin","genericName":"Low dose dalteparin","slug":"low-dose-dalteparin","indication":"Venous thromboembolism prophylaxis in surgical patients","status":"marketed"},{"name":"Intermediate dose nadroparin","genericName":"Intermediate dose nadroparin","slug":"intermediate-dose-nadroparin","indication":"Thromboprophylaxis in surgical patients","status":"marketed"},{"name":"Intermediate dose tinzaparin","genericName":"Intermediate dose tinzaparin","slug":"intermediate-dose-tinzaparin","indication":"Thromboprophylaxis in surgical patients","status":"marketed"},{"name":"Low dose nadroparin","genericName":"Low dose nadroparin","slug":"low-dose-nadroparin","indication":"Thromboprophylaxis in surgical patients","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"Fluticasone proprionate 0.05% cream","genericName":"Fluticasone proprionate 0.05% cream","slug":"fluticasone-proprionate-0-05-cream","indication":"Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis)","status":"marketed"},{"name":"Infliximab subcutaneous","genericName":"Infliximab subcutaneous","slug":"infliximab-subcutaneous","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"PRECISION dosing Infliximab","genericName":"PRECISION dosing Infliximab","slug":"precision-dosing-infliximab","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"anti-tumour necrosis factor α antibodies","genericName":"anti-tumour necrosis factor α antibodies","slug":"anti-tumour-necrosis-factor-antibodies","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Mercaptopurine (Purinethol)","genericName":"Mercaptopurine (Purinethol)","slug":"mercaptopurine-purinethol","indication":"Acute lymphoblastic leukemia (ALL)","status":"phase_3"},{"name":"Targeted Systemic Therapy","genericName":"Targeted Systemic Therapy","slug":"targeted-systemic-therapy","indication":"Cancer (specific indication unknown)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Rapidly Cycled HAART","genericName":"Rapidly Cycled HAART","slug":"rapidly-cycled-haart","indication":"HIV-1 infection","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"ferric(III)carboxymaltose","genericName":"ferric(III)carboxymaltose","slug":"ferric-iii-carboxymaltose","indication":"Iron deficiency anemia in adults","status":"marketed"}]}],"pipeline":[{"name":"Endotoxin","genericName":"Endotoxin","slug":"endotoxin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fixed low dose tinzaparin","genericName":"Fixed low dose tinzaparin","slug":"fixed-low-dose-tinzaparin","phase":"marketed","mechanism":"Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","indications":["Thromboprophylaxis in medical patients","Thromboprophylaxis in surgical patients"],"catalyst":""},{"name":"Intermediate dose dalteparin","genericName":"Intermediate dose dalteparin","slug":"intermediate-dose-dalteparin","phase":"marketed","mechanism":"Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.","indications":["Thromboembolism prophylaxis and treatment","Acute coronary syndrome","Venous thromboembolism prevention and treatment"],"catalyst":""},{"name":"Intermediate dose enoxaparin","genericName":"Intermediate dose enoxaparin","slug":"intermediate-dose-enoxaparin","phase":"marketed","mechanism":"Intermediate dose enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","indications":["Thromboprophylaxis in medical and surgical patients","Treatment of acute deep vein thrombosis and pulmonary embolism","Acute coronary syndrome"],"catalyst":""},{"name":"Low dose dalteparin","genericName":"Low dose dalteparin","slug":"low-dose-dalteparin","phase":"marketed","mechanism":"Low-dose dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.","indications":["Venous thromboembolism prophylaxis in surgical patients","Venous thromboembolism prophylaxis in medical patients with reduced mobility","Treatment of acute deep vein thrombosis and pulmonary embolism"],"catalyst":""},{"name":"Cephalozin","genericName":"Cephalozin","slug":"cephalozin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fluticasone proprionate 0.05% cream","genericName":"Fluticasone proprionate 0.05% cream","slug":"fluticasone-proprionate-0-05-cream","phase":"marketed","mechanism":"Fluticasone propionate is a potent topical corticosteroid that suppresses local inflammatory and immune responses in the skin.","indications":["Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis)"],"catalyst":""},{"name":"Infliximab subcutaneous","genericName":"Infliximab subcutaneous","slug":"infliximab-subcutaneous","phase":"phase_3","mechanism":"Infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Intermediate dose nadroparin","genericName":"Intermediate dose nadroparin","slug":"intermediate-dose-nadroparin","phase":"marketed","mechanism":"Nadroparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.","indications":["Thromboprophylaxis in surgical patients","Treatment of deep vein thrombosis","Treatment of pulmonary embolism","Acute coronary syndrome"],"catalyst":""},{"name":"Intermediate dose tinzaparin","genericName":"Intermediate dose tinzaparin","slug":"intermediate-dose-tinzaparin","phase":"marketed","mechanism":"Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","indications":["Thromboprophylaxis in surgical patients","Treatment of deep vein thrombosis","Treatment of pulmonary embolism","Acute coronary syndrome"],"catalyst":""},{"name":"Low dose nadroparin","genericName":"Low dose nadroparin","slug":"low-dose-nadroparin","phase":"marketed","mechanism":"Low-dose nadroparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.","indications":["Thromboprophylaxis in surgical patients","Thromboprophylaxis in medical patients at risk of venous thromboembolism","Treatment of deep vein thrombosis","Treatment of pulmonary embolism"],"catalyst":""},{"name":"Mercaptopurine (Purinethol)","genericName":"Mercaptopurine (Purinethol)","slug":"mercaptopurine-purinethol","phase":"phase_3","mechanism":"Mercaptopurine is a purine analog that inhibits de novo purine synthesis and is converted to active metabolites that interfere with DNA and RNA synthesis, leading to cell death.","indications":["Acute lymphoblastic leukemia (ALL)","Chronic myeloid leukemia (CML)","Inflammatory bowel disease (Crohn's disease, ulcerative colitis)"],"catalyst":""},{"name":"Nanocort","genericName":"Nanocort","slug":"nanocort","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PRECISION dosing Infliximab","genericName":"PRECISION dosing Infliximab","slug":"precision-dosing-infliximab","phase":"marketed","mechanism":"Infliximab is a TNF-alpha inhibitor monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha to reduce inflammatory responses.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Placebo (for flucloxacillin)","genericName":"Placebo (for flucloxacillin)","slug":"placebo-for-flucloxacillin","phase":"marketed","mechanism":"A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.","indications":["Control comparator in clinical research (not a therapeutic indication)"],"catalyst":""},{"name":"Rapidly Cycled HAART","genericName":"Rapidly Cycled HAART","slug":"rapidly-cycled-haart","phase":"marketed","mechanism":"Rapidly Cycled HAART is a highly active antiretroviral therapy regimen that uses rapid rotation or cycling of different antiretroviral drug classes to suppress HIV replication and potentially reduce resistance development.","indications":["HIV-1 infection"],"catalyst":""},{"name":"Reduced noradrenaline use","genericName":"Reduced noradrenaline use","slug":"reduced-noradrenaline-use","phase":"marketed","mechanism":"Reduced noradrenaline use refers to a clinical practice or protocol aimed at minimizing the administration of noradrenaline (norepinephrine) in patient care.","indications":["Septic shock or other conditions requiring vasopressor support in intensive care"],"catalyst":""},{"name":"S-1 and Oxaliplatin","genericName":"S-1 and Oxaliplatin","slug":"s-1-and-oxaliplatin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Targeted Systemic Therapy","genericName":"Targeted Systemic Therapy","slug":"targeted-systemic-therapy","phase":"phase_3","mechanism":"Targeted Systemic Therapy is a cancer treatment designed to selectively target and destroy malignant cells while minimizing damage to healthy tissue.","indications":["Cancer (specific indication unknown)"],"catalyst":""},{"name":"Vancomycin, Metronidazole, Ciprofloxacin","genericName":"Vancomycin, Metronidazole, Ciprofloxacin","slug":"vancomycin-metronidazole-ciprofloxacin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"anti-tumour necrosis factor α antibodies","genericName":"anti-tumour necrosis factor α antibodies","slug":"anti-tumour-necrosis-factor-antibodies","phase":"phase_3","mechanism":"Anti-TNF-α antibodies bind to and neutralize tumor necrosis factor alpha, a key pro-inflammatory cytokine, thereby reducing inflammation and immune-mediated tissue damage.","indications":["Rheumatoid arthritis","Inflammatory bowel disease (Crohn's disease and ulcerative colitis)","Ankylosing spondylitis","Psoriasis and psoriatic arthritis"],"catalyst":""},{"name":"ferric(III)carboxymaltose","genericName":"ferric(III)carboxymaltose","slug":"ferric-iii-carboxymaltose","phase":"marketed","mechanism":"Ferric carboxymaltose is an iron replacement therapy that delivers ferric iron complexed with carboxymaltose to replenish depleted iron stores and treat iron deficiency anemia.","indications":["Iron deficiency anemia in adults","Iron deficiency anemia in patients with chronic kidney disease","Iron deficiency anemia in patients intolerant to or with inadequate response to oral iron"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":22,"phaseCounts":{"marketed":15,"phase_3":4,"phase_1":2,"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}